Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dimethylhydrazine | decreases expression | ISO | Ss18l2 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of SS18L2 mRNA | CTD | PMID:22206623 | 1,2-dimethylhydrazine | multiple interactions | ISO | Ss18l2 (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of SS18L2 mRNA | CTD | PMID:22206623 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Ss18l2 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of SS18L2 mRNA | CTD | PMID:21570461 | 2-hydroxypropanoic acid | decreases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | Lactic Acid results in decreased expression of SS18L2 mRNA | CTD | PMID:30851411 | 2-palmitoylglycerol | increases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | 2-palmitoylglycerol results in increased expression of SS18L2 mRNA | CTD | PMID:37199045 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | SS18L2 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SS18L2 mRNA | CTD | PMID:28628672 | 4,4'-diaminodiphenylmethane | affects expression | ISO | Ss18l2 (Mus musculus) | 6480464 | 4 and 4'-diaminodiphenylmethane affects the expression of SS18L2 mRNA | CTD | PMID:18648102 | 4,4'-sulfonyldiphenol | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of SS18L2 mRNA | CTD | PMID:36041667 | antirheumatic drug | decreases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | Antirheumatic Agents results in decreased expression of SS18L2 mRNA | CTD | PMID:24449571 | benzo[a]pyrene | affects methylation | ISO | SS18L2 (Homo sapiens) | 6480464 | Benzo(a)pyrene affects the methylation of SS18L2 promoter | CTD | PMID:27901495 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | 7 more ... | CTD | PMID:20382639 | bisphenol A | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of SS18L2 mRNA | CTD | PMID:36041667 | bisphenol F | multiple interactions | ISO | SS18L2 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SS18L2 mRNA | CTD | PMID:28628672 | bisphenol F | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of SS18L2 mRNA | CTD | PMID:36041667 | cadmium atom | multiple interactions | ISO | SS18L2 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SS18L2 mRNA | CTD | PMID:35301059 | cadmium dichloride | multiple interactions | ISO | SS18L2 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SS18L2 mRNA | CTD | PMID:35301059 | carbamazepine | affects expression | ISO | SS18L2 (Homo sapiens) | 6480464 | Carbamazepine affects the expression of SS18L2 mRNA | CTD | PMID:25979313 | chloropicrin | decreases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | chloropicrin results in decreased expression of SS18L2 mRNA | CTD | PMID:26352163 | cisplatin | increases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | Cisplatin results in increased expression of SS18L2 mRNA | CTD | PMID:19561079 | clobetasol | increases expression | ISO | Ss18l2 (Mus musculus) | 6480464 | Clobetasol results in increased expression of SS18L2 mRNA | CTD | PMID:27462272 | copper(II) sulfate | decreases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | Copper Sulfate results in decreased expression of SS18L2 mRNA | CTD | PMID:19549813 | dexamethasone | multiple interactions | ISO | SS18L2 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SS18L2 mRNA | CTD | PMID:28628672 | dicrotophos | decreases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | dicrotophos results in decreased expression of SS18L2 mRNA | CTD | PMID:28302478 | disodium selenite | increases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | Sodium Selenite results in increased expression of SS18L2 mRNA | CTD | PMID:18175754 | dorsomorphin | multiple interactions | ISO | SS18L2 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SS18L2 mRNA | CTD | PMID:27188386 | elemental selenium | decreases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | Selenium results in decreased expression of SS18L2 mRNA | CTD | PMID:19244175 | ethanol | multiple interactions | ISO | SS18L2 (Homo sapiens) | 6480464 | [[Gasoline co-treated with Ethanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SS18L2 mRNA | CTD | PMID:29432896 | ethyl methanesulfonate | decreases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | Ethyl Methanesulfonate results in decreased expression of SS18L2 mRNA | CTD | PMID:23649840 | folic acid | multiple interactions | ISO | Ss18l2 (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of SS18L2 mRNA | CTD | PMID:22206623 | fumonisin B1 | decreases expression | ISO | Ss18l2 (Mus musculus) | 6480464 | fumonisin B1 results in decreased expression of SS18L2 mRNA | CTD | PMID:16221962 | glafenine | increases expression | EXP | | 6480464 | Glafenine results in increased expression of SS18L2 mRNA | CTD | PMID:24136188 | hydrogen peroxide | affects expression | ISO | SS18L2 (Homo sapiens) | 6480464 | Hydrogen Peroxide affects the expression of SS18L2 mRNA | CTD | PMID:20044591 | indometacin | multiple interactions | ISO | SS18L2 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SS18L2 mRNA | CTD | PMID:28628672 | leflunomide | decreases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | leflunomide results in decreased expression of SS18L2 mRNA | CTD | PMID:28988120 | methyl methanesulfonate | decreases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | Methyl Methanesulfonate results in decreased expression of SS18L2 mRNA | CTD | PMID:23649840 | nimesulide | increases expression | EXP | | 6480464 | nimesulide results in increased expression of SS18L2 mRNA | CTD | PMID:24136188 | paracetamol | affects expression | ISO | Ss18l2 (Mus musculus) | 6480464 | Acetaminophen affects the expression of SS18L2 mRNA | CTD | PMID:17562736 | phenobarbital | affects expression | ISO | SS18L2 (Homo sapiens) | 6480464 | Phenobarbital affects the expression of SS18L2 mRNA | CTD | PMID:19159669 | phenol | decreases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | Phenol results in decreased expression of SS18L2 mRNA | CTD | PMID:17547211 | rac-lactic acid | decreases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | Lactic Acid results in decreased expression of SS18L2 mRNA | CTD | PMID:30851411 | SB 431542 | multiple interactions | ISO | SS18L2 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SS18L2 mRNA | CTD | PMID:27188386 | selenium atom | decreases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | Selenium results in decreased expression of SS18L2 mRNA | CTD | PMID:19244175 | testosterone | multiple interactions | ISO | Ss18l2 (Mus musculus) | 6480464 | 1 more ... | CTD | PMID:33848595 | testosterone | decreases expression | ISO | Ss18l2 (Mus musculus) | 6480464 | Testosterone deficiency results in decreased expression of SS18L2 mRNA | CTD | PMID:33848595 | tolcapone | decreases expression | EXP | | 6480464 | tolcapone results in decreased expression of SS18L2 mRNA | CTD | PMID:24136188 | trichostatin A | decreases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of SS18L2 mRNA | CTD | PMID:24935251 and PMID:26272509 | trichostatin A | multiple interactions | ISO | SS18L2 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SS18L2 mRNA | CTD | PMID:27188386 | valproic acid | increases expression | ISO | Ss18l2 (Mus musculus) | 6480464 | Valproic Acid results in increased expression of SS18L2 mRNA | CTD | PMID:20546886 | vorinostat | increases expression | ISO | SS18L2 (Homo sapiens) | 6480464 | vorinostat results in increased expression of SS18L2 mRNA | CTD | PMID:27188386 | |